{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T01:57:05Z","timestamp":1762999025129},"reference-count":33,"publisher":"BMJ","issue":"Suppl 4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"accepted":{"date-parts":[[2013,8,29]]},"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p><jats:italic>Neisseria gonorrhoeae<\/jats:italic>has progressively developed resistance to sulfonamides, penicillin, tetracycline and fluoroquinolones, and gonococcal susceptibility to cephalosporins has been declining worldwide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We described trends in gonococcal antimicrobial susceptibility in the USA from January 2006 through June 2012. Susceptibility data for cefixime, ceftriaxone, azithromycin, penicillin, tetracycline and ciprofloxacin were obtained from the Gonococcal Isolate Surveillance Project (GISP), a sentinel surveillance system that monitors antimicrobial susceptibility in urethral gonococcal isolates collected from symptomatic men at 25\u201330 sexually transmitted disease clinics throughout the USA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The percentage of isolates with elevated cefixime minimum inhibitory concentrations (MICs) (\u22650.25\u2005\u00b5g\/mL) increased from 0.1% in 2006 to 1.4% in 2010\u20132011 and was 1.1% in the first 6\u2005months of 2012. The percentage with elevated ceftriaxone MICs (\u22650.125\u2005\u00b5g\/mL) increased from 0.1% in 2006 to 0.3%\u20130.4% during 2009 through the first 6\u2005months of 2012. There were no temporal trends in the prevalence of elevated azithromycin MICs (\u22652\u2005\u00b5g\/mL) (0.2%\u20130.5%). The prevalence of resistance remained high for penicillin (11.2%\u201313.2%), tetracycline (16.7%\u201322.8%) and ciprofloxacin (9.6%\u201314.8%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The proportion of gonococcal isolates with elevated cephalosporin MICs increased from 2006 to 2010, but plateaued during 2011 and the first 6\u2005months of 2012. Resistance to previously recommended antimicrobials has persisted. As the number of antimicrobials available for gonorrhoea treatment dwindles, surveillance systems such as GISP will be critical to detect emerging resistance trends and guide treatment decisions.<\/jats:p><\/jats:sec>","DOI":"10.1136\/sextrans-2013-051162","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T14:33:46Z","timestamp":1384526026000},"page":"iv5-iv10","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":58,"title":["Trends in antimicrobial resistance in<i>Neisseria gonorrhoeae<\/i>in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006\u2013June 2012"],"prefix":"10.1136","volume":"89","author":[{"given":"Robert D","family":"Kirkcaldy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillard S","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R","family":"Papp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail A","family":"Bolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,11,15]]},"reference":[{"key":"2024051410205161000_89.Suppl_4.iv5.1","first-page":"1","article-title":"Summary of notifiable diseases\u2014United States, 2010","volume":"59","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR"},{"key":"2024051410205161000_89.Suppl_4.iv5.2","unstructured":"Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2011. Atlanta: U.S. Department of Health and Human Services, 2012."},{"key":"2024051410205161000_89.Suppl_4.iv5.3","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e318286bb53"},{"key":"2024051410205161000_89.Suppl_4.iv5.4","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-198304000-00007"},{"issue":"(5S)","key":"2024051410205161000_89.Suppl_4.iv5.5","first-page":"1S","article-title":"Antibiotic-resistant strains of Neisseria gonorrhoeae. Policy guidelines for detection, management, and control","volume":"36","author":"Centers for Disease Control and Prevention","year":"1987","journal-title":"MMWR"},{"issue":"(S-8)","key":"2024051410205161000_89.Suppl_4.iv5.6","first-page":"1","article-title":"1989 Sexually transmitted diseases treatment guidelines","volume":"38","author":"Centers for Disease Control and Prevention","year":"1989","journal-title":"MMWR"},{"key":"2024051410205161000_89.Suppl_4.iv5.7","first-page":"1041","article-title":"Increases in fluoroquinolone-resistant Neisseria gonorrhoeae\u2014Hawaii and California, 2001","volume":"51","author":"Centers for Disease Control and Prevention","year":"2002","journal-title":"MMWR"},{"key":"2024051410205161000_89.Suppl_4.iv5.8","first-page":"335","article-title":"Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men\u2014United States, 2003, and revised recommendations for treatment, 2004","volume":"53","author":"Centers for Disease Control and Prevention","year":"2004","journal-title":"MMWR"},{"key":"2024051410205161000_89.Suppl_4.iv5.9","first-page":"332","article-title":"Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2006: fluoroquinolones are no longer recommended for treatment of gonococcal infections","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"MMWR"},{"key":"2024051410205161000_89.Suppl_4.iv5.10","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.117"},{"key":"2024051410205161000_89.Suppl_4.iv5.11","first-page":"873","article-title":"Cephalosporin susceptibility among Neisseria gonorrhoeae isolates\u2014United States, 2000\u20132010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR"},{"key":"2024051410205161000_89.Suppl_4.iv5.12","first-page":"590","article-title":"Update to CDC's sexually transmitted diseases treatment guidelines, 2010: Oral cephalosporins no longer recommended for treatment of gonococcal infections","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR"},{"key":"2024051410205161000_89.Suppl_4.iv5.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450110059027"},{"key":"2024051410205161000_89.Suppl_4.iv5.14","unstructured":"Centers for Disease Control and Prevention. Gonococcal Isolate Surveillance Project (GISP) Protocol. 2010. http:\/\/www.cdc.gov\/std\/gisp\/GISP-Protocol07\u201315\u20132010.pdf"},{"key":"2024051410205161000_89.Suppl_4.iv5.15","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement. CLSI document M100-S21. Wayne, PA: Clinical and Laboratory Standards Institute, 2011."},{"key":"2024051410205161000_89.Suppl_4.iv5.16","unstructured":"Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2010. Atlanta: U.S. Department of Health and Human Services, 2011."},{"key":"2024051410205161000_89.Suppl_4.iv5.17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-5-201303050-00004"},{"key":"2024051410205161000_89.Suppl_4.iv5.18","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2011.300283"},{"key":"2024051410205161000_89.Suppl_4.iv5.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06215.x"},{"key":"2024051410205161000_89.Suppl_4.iv5.20","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis277"},{"issue":"(Suppl 1)","key":"2024051410205161000_89.Suppl_4.iv5.21","first-page":"S57","article-title":"Drugs of choice for the treatment of uncomplicated gonococcal infections","volume":"20","author":"Moran","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2024051410205161000_89.Suppl_4.iv5.22","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-197904000-00021"},{"key":"2024051410205161000_89.Suppl_4.iv5.23","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e31827bd64c"},{"key":"2024051410205161000_89.Suppl_4.iv5.24","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh220"},{"key":"2024051410205161000_89.Suppl_4.iv5.25","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2004.011049"},{"key":"2024051410205161000_89.Suppl_4.iv5.26","unstructured":"Centers for Disease Control and Prevention. 1993 Sexually Transmitted Diseases Treatment Guidelines. MMWR 1993;42 (RR-14)."},{"key":"2024051410205161000_89.Suppl_4.iv5.27","unstructured":"Centers for Disease Control and Prevention. 1998 Guidelines for Treatment of Sexually Transmitted Diseases. MMWR 1998;47 (RR-1)."},{"key":"2024051410205161000_89.Suppl_4.iv5.28","unstructured":"Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2002. MMWR 2002;51 (RR-6)."},{"key":"2024051410205161000_89.Suppl_4.iv5.29","doi-asserted-by":"crossref","unstructured":"Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2006. MMWR 2006;55 (RR-11).","DOI":"10.1016\/S0300-7073(06)73354-0"},{"key":"2024051410205161000_89.Suppl_4.iv5.30","unstructured":"Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR 2010;59 (RR-12)."},{"key":"2024051410205161000_89.Suppl_4.iv5.31","doi-asserted-by":"publisher","DOI":"10.1097\/01.OLQ.0000124609.84050.F3"},{"key":"2024051410205161000_89.Suppl_4.iv5.32","doi-asserted-by":"publisher","DOI":"10.1097\/01.olq.0000222708.70594.8e"},{"key":"2024051410205161000_89.Suppl_4.iv5.33","unstructured":"Yee E Satterwhite C Braxton J . Sexually transmitted diseases testing practices in the US in public health laboratories, 2007. International Society for Sexually Transmitted Diseases Research Conference. London, UK, 2009 (poster presentation)."}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2013-051162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T17:21:20Z","timestamp":1715707280000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2013-051162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,15]]},"references-count":33,"journal-issue":{"issue":"Suppl 4","published-online":{"date-parts":[[2013,11,15]]},"published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1136\/sextrans-2013-051162"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2013-051162","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"value":"1368-4973","type":"print"},{"value":"1472-3263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,15]]}}}